Serum Glial Cell Line-Derived Neurotrophic Factor (sGDNF) Is a Novel Biomarker in Predicting Cirrhosis in Patients with Chronic Hepatitis B.
Serum Glial Cell Line-Derived Neurotrophic Factor (sGDNF) Is a Novel Biomarker in Predicting Cirrhosis in Patients with Chronic Hepatitis B.
复制标题
DOI：
10.1155/2022/1048104
复制
发表时间：
2022
影响因子：
2.7
通讯作者：
Liu, Cheng
中科院分区：
文献类型：
--
作者：
Yang, Guangyue;Zhuang, Liping;Sun, Tiantian;Yeo, Yee Hui;Tao, Le;Zhang, Wei;Ma, Wenting;Wu, Liu;Yang, Zongguo;Yang, Yanqin;Xue, Dongying;Zhang, Jie;Feng, Rilu;Matthias, Ebert P.;Dooley, Steven;Seki, Ekihiro;Liu, Ping;Liu, Cheng
我们评估了胶质细胞源性神经营养因子（GDNF）作为预测慢性B型肝炎（CH B）患者肝硬化的有用生物标志物的潜力。 来自两个医学中心的735名患者（385名CHB患者和350名健康对照）被纳入，以确定血清和组织GDNF水平与活检证实的肝硬化的相关性。评价血清GDNF（sGDNF）对肝硬化诊断的准确性，并与其他指标进行比较。 我们发现，慢性乙型肝炎伴纤维化患者（28.4 pg/ml vs.无纤维化患者11.6 pg/ml）和肝硬化患者（33.8 pg/ml vs.无纤维化患者23.5 pg/ml）的sGDNF水平显著较高。sGDNF预测肝纤维化的受试者工作曲线下面积（AUROC）为0.83（95%CI：0.80-0.87），预测肝硬化的AUROC为0.84（95%CI：0.79-0.89）。血清蛋白水平和肝脏mRNA表达的结果一致。使用预测肝硬化的最佳截止值，我们将患者分为sGDNF高和sGDNF低组。高sGDNF组具有显著更大的Masson三色和网硬蛋白染色阳性面积、更高的Scheuer评分和METAVIR纤维化分期（所有p < 0.001），但没有脂肪变性。在多变量回归分析中，sGDNF与肝硬化独立相关，比值比为6.98（95%CI：1.10-17.94）。最后，我们证明sGDNF在区分F4与F3方面优于AST与血小板比率指数、FIB-4、纤维评分、forn指数和纤维测定仪。 利用血清、组织mRNA和活检数据，我们的研究揭示了sGDNF作为CHB患者肝硬化新型非侵入性生物标志物的巨大潜力。
We assessed the potential of glial cell line-derived neurotrophic factor (GDNF) as a useful biomarker to predict cirrhosis in chronic hepatitis B (CHB) patients. A total of 735 patients from two medical centers (385 CHB patients and 350 healthy controls) were included to determine the association of serum and tissue GDNF levels with biopsy-proven cirrhosis. The diagnostic accuracy of serum GDNF (sGDNF) was estimated and compared with other indices of cirrhosis. We showed significantly higher levels of sGDNF in CHB patients with fibrosis (28.4 pg/ml vs. 11.6 pg/ml in patients without) and patients with cirrhosis (33.8 pg/ml vs. 23.5 pg/ml in patients without). The areas under receiver operating curve (AUROCs) of sGDNF were 0.83 (95% confidence interval (CI): 0.80–0.87) for predicting liver fibrosis and 0.84 (95% CI: 0.79–0.89) for cirrhosis. Findings from the serum protein level and hepatic mRNA expression were consistent. Using the best cutoff to predict cirrhosis, we categorized the patients into sGDNF-high and sGDNF-low groups. The sGDNF-high group had significantly larger Masson's trichrome and reticulin staining-positive area, higher Scheuer score, and METAVIR fibrosis stage (all p < 0.001) but not steatosis. On multivariable regression, sGDNF was independently associated with cirrhosis with an odds ratio of 6.98 (95% CI: 1.10–17.94). Finally, we demonstrated that sGDNF outperformed AST to platelet ratio index, FIB-4, fibroscore, forn index, and fibrometer in differentiating F4 vs. F3. Using serum, tissue mRNA, and biopsy data, our study revealed a significant potential of sGDNF as a novel noninvasive biomarker for cirrhosis in CHB patients.
登录
查看更多内容
影响因子：
--
作者：
Huber RM;Lucas JM;Gomez-Sarosi LA;Coleman I;Zhao S;Coleman R;Nelson PS
通讯作者：
Nelson PS
影响因子：
3.7
作者：
Axley P;Mudumbi S;Sarker S;Kuo YF;Singal AK
通讯作者：
Singal AK
高尔基体蛋白 73 和肝脏硬度的算法可准确诊断慢性 HBV 感染的显着纤维化。
影响因子：
6.7
作者：
Cao, Zhujun;Li, Ziqiang;Xie, Qing
通讯作者：
Xie, Qing
影响因子：
6.6
作者：
Jeon, Mi Young;Lee, Hye Won;Han, Kwang-Hyub
通讯作者：
Han, Kwang-Hyub
影响因子：
56.9
作者：
LIN, LFH;DOHERTY, DH;COLLINS, F
通讯作者：
COLLINS, F